Synergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity

Condition studied

Recurrent Glioblastoma

Investigational medicinal product(s)

Eligibility

Primary endpoint

Immunological responsiveness of blood T cells as determined by interferon-gamma and multi-cytokine responses towards tumor lysate-loaded DC during vaccination.

Endpoint detail

Feasibility (production and application of therapeutics)., Safety based on the frequency and severity of AE with toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)., Survival based on overall and progression-free survival (according to modified Response Assessment in Neuro-Oncology (RANO) criteria) at six months after surgery.